

Citations

1. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. *Carcinogenesis* 1999;20:1657-1666.
2. Panel on Dietary Antioxidants and Related Compounds, Food and Nutrition Board. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academy Press, Washington, DC: Institute of Medicine, National Academy of Sciences; 2000.
3. Yang G, Zhou R. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. *J Trace Elem Electrolytes Health Dis* 1994;8:159-165.
- 3a. Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;147(4):217-223.
4. Contempre B, Dumont JE, Ngo B et al. Effect of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: the possible danger of indiscriminate supplementation of iodine-deficient subjects with selenium. *J Clin Endocrinol Metab* 1991;73:213-215.
5. Duffield-Lillico AJ, Slate EH, Reid ME et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2003;95:1477-1481.
6. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. *Toxicology* 2003;189:1-20.
7. Sieja K. Protective role of selenium against the toxicity of multi-drug chemotherapy in patients with ovarian cancer. *Pharmazie* 2000;55:958-959.
8. Last KW, Cornelius V, Delves T et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2003;21:2335-2341.
9. Sieja K, Talerzyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. *Gynecol Oncol* 2004;93:320-327.
10. Baldew GS, Mol JG, de Kanter FJ et al. The mechanism of interaction between cisplatin and selenite. *Biochem Pharmacol* 1991;41:1429-1437.
11. Vernie LN, de Goeij JJ, Zegers C et al. Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients. *Cancer Lett* 1988;40:83-91.
12. Baldew GS, van den Hamer CJ, Los G et al. Selenium-induced protection against cis-diaminedichloroplatinum(II) nephrotoxicity in mice and rats. *Cancer Res* 1989;49:3020-3023.
13. Vermeulen NP, Baldew GS, Los G et al. Reduction of cisplatin nephrotoxicity by sodium selenite: lack of interaction at the pharmacokinetic level of both compounds. *Drug Metab Dispos* 1993;21:30-36.
14. Ohkawa K, Tsukada Y, Dohzono H et al. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. *Br J Cancer* 1988;58:38-41.
15. Hu YJ, Chen Y, Zhang YQ et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. *Biol Trace Elem Res* 1997;56:331-341.
16. Sundstrom H, Korpela H, Sajanti E, Kauppila A. Supplementation with selenium, vitamin E and their combination in gynaecological cancer during cytotoxic chemotherapy. *Carcinogenesis* 1989;10:273-278.
17. Olas B, Wachowicz B. [Selenium in the cytotoxicity of cisplatin]. *Postepy Hig Med Dosw* 1997;51:95-108.
18. Lindsay LA, Pippenger CE, Howard A, Lieberman JA. Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. *J Clin Psychopharmacol* 1995;15:353-360.
19. Williams DP, Pirmohamed M, Naisbitt DJ et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. *J Pharmacol Exp Ther* 1997;283:1375-1382.
20. Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. *Br J Clin Pharmacol* 2003;55:307-309.
21. Peretz A, Neve J, Vertongen F et al. Selenium status in relation to clinical variables and corticosteroid treatment in rheumatoid arthritis. *J Rheumatol* 1987;14:1104-1107.
22. Peretz AM, Neve JD, Famaey JP. Selenium in rheumatic diseases. *Semin Arthritis Rheum* 1991;20:305-316.
23. Tarp U. Selenium in rheumatoid arthritis: a review. *Analyst* 1995;120:877-881.
24. Navarro-Alarcon M, Lopez-Martinez MC. Essentiality of selenium in the human body: relationship with different diseases. *Sci Total Environ* 2000;249:347-371.
25. Ames BN. Micronutrient deficiencies: a major cause of DNA damage. *Ann N Y Acad Sci* 1999;889:87-106.
26. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. *FASEB J* 1997;11:931-936.
27. Singal PK, Li T, Kumar D et al. Adriamycin-induced heart failure: mechanism and modulation. *Mol Cell Biochem* 2000;207:77-86.
28. Quiles JL, Huertas JR, Battino M et al. Antioxidant nutrients and Adriamycin toxicity. *Toxicology* 2002;180:79-95.

Citations and Reference Literature: Selenium

29. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. *Br Heart J* 1986;55:274-282.
30. Mortensen SA, Aabo K, Jonsson T, Baandrup U. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. *Int J Clin Pharmacol Res* 1986;6:137-150.
31. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *JAMA* 1991;266:1672-1677.
32. Chen XS, Xue A, Morris VC et al. Effect of selenium deficiency on the chronic toxicity of Adriamycin in rats. *J Nutr* 1986;116:2453-2465.
33. Nakano E, Takeshige K, Toshima Y et al. Oxidative damage in selenium deficient hearts on perfusion with Adriamycin: protective role of glutathione peroxidase system. *Cardiovasc Res* 1989;23:498-504.
34. Coudray C, Mouhieddine S, Richard MJ et al. Effects of Adriamycin on chronic cardiotoxicity in selenium-deficient rats. *Basic Res Cardiol* 1992;87:173-183.
35. Matsuda A, Kimura M, Itokawa Y. Influence of selenium deficiency on the acute cardiotoxicity of Adriamycin in rats. *Biol Trace Elem Res* 1997;57:157-167.
36. Fischer JG, Tackett RL, Howerth EW, Johnson MA. Copper and selenium deficiencies do not enhance the cardiotoxicity in rats due to chronic doxorubicin treatment. *J Nutr* 1992;122:2128-2137.
37. Sokolove PM, Kester MB, Haynes J. Interaction of Adriamycin aglycones with isolated mitochondria: effect of selenium deficiency. *Biochem Pharmacol* 1993;46:691-697.
38. Van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. *Am J Pathol* 1980;99:13-42.
39. Hermansen K, Wassermann K. The effect of vitamin E and selenium on doxorubicin (Adriamycin) induced delayed toxicity in mice. *Acta Pharmacol Toxicol (Copenh)* 1986;58:31-37.
40. Van Vleet JF, Ferrans VJ. Evaluation of vitamin E and selenium protection against chronic Adriamycin toxicity in rabbits. *Cancer Treat Rep* 1980;64:315-317.
41. Van Vleet JF, Greenwood LA, Rebar AH. Effect of selenium-vitamin E on hematologic alterations of Adriamycin toxicosis in young pigs. *Am J Vet Res* 1981;42:1153-1159.
42. Dimitrov NV, Hay MB, Siew S et al. Abrogation of Adriamycin-induced cardiotoxicity by selenium in rabbits. *Am J Pathol* 1987;126:376-383.
43. Boucher F, Coudray C, Tirard V et al. Oral selenium supplementation in rats reduces cardiac toxicity of Adriamycin during ischemia and reperfusion. *Nutrition* 1995;11:708-711.
44. Vadgama JV, Wu Y, Shen D et al. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. *Anticancer Res* 2000;20:1391-1414.
45. Heese HD, Lawrence MA, Dempster WS, Pocock F. Reference concentrations of serum selenium and manganese in healthy nulliparas. *S Afr Med J* 1988;73:163-165.
46. L'Abbe MR, Collins MW, Trick KD, Laffey PJ. Glutathione peroxidase activity in a healthy Canadian population: effects of age, smoking and drinking habits, exercise and oral contraceptive use. *Trace Elem Med* 1992;9:45-53.
47. Hurd RW, Van Rinsvelt HA, Wilder BJ et al. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. *Neurology* 1984;34:1393-1395.
48. Nurge ME, Anderson CR, Bates E. Metabolic and nutritional implications of valproic acid. *Nutr Res* 1991;11:949-960.
49. Graf WD, Oleinik OE, Glauser TA et al. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. *Neuropediatrics* 1998;29:195-201.
50. Buchi KN, Gray PD, Rollins DE, Tolman KG. Protection against sodium valproate injury in isolated hepatocytes by alpha-tocopherol and N,N'-diphenyl-p-phenylenediamine. *J Clin Pharmacol* 1984;24:148-154.
51. Kurekci AE, Alpay F, Tanindi S et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. *Epilepsia* 1995;36:600-604.
52. Verrotti A, Basciani F, Trotta D et al. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. *Epilepsy Res* 2002;48:71-75.
53. Khaidakov M, Bishop ME, Manjanatha MG et al. Influence of dietary antioxidants on the mutagenicity of 7,12-dimethylbenz[a]anthracene and bleomycin in female rats. *Mutat Res* 2001;480-481:163-170.
54. Desai VG, Casciano D, Feuers RJ, Aidoo A. Activity profile of glutathione-dependent enzymes and respiratory chain complexes in rats supplemented with antioxidants and treated with carcinogens. *Arch Biochem Biophys* 2001;394:255-264.
55. Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. *J Am Coll Cardiol* 2000;36:1774-1780.

Citations and Reference Literature: Selenium

56. Cheung MC, Zhao XQ, Chait A et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. *Arterioscler Thromb Vasc Biol* 2001;21:1320-1326.
57. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583-1592.
58. Gramm HJ, Kopf A, Bratter P. [Importance and physiologic nutritional requirement of the selenium trace element within the scope of parenteral nutrition (TPN)]. *Med Klin* 1997;92 Suppl 3:20-22.
59. Itokawa Y. [Trace elements in long-term total parenteral nutrition]. *Nippon Rinsho* 1996;54:172-178.
60. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C: combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. *Med Klin* 1999;94 Suppl 3:84-89.

Reference Literature

- Ames BN. An enthusiasm for metabolism. *J Biol Chem* 2003;278(7):4369-4380. (Review)
- Ames BN. Delaying the mitochondrial decay of aging. *Ann N Y Acad Sci* 2004;1019:406-411. (Review)
- Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutat Res* 2001;475(1-2):7-20. (Review)
- Ames BN. Increasing longevity by tuning up metabolism: to maximize human health and lifespan, scientists must abandon outdated models of micronutrients. *EMBO Rep* 2005;6(Suppl 1):S20-24.
- Ames BN. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. *Proc Natl Acad Sci U S A* 2006;103:17589-17594.
- Ames BN. The metabolic tune-up: metabolic harmony and disease prevention. *J Nutr* 2003;133(5):1544S-1548S.
- Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol Aspects Med* 2005;26(4-5):363-378. (Review)
- Badmaev V, Majeed M, Passwater RA. Selenium: a quest for better understanding. *Altern Ther Health Med* 1996;2(4):59-57.
- Bardia A, Tleyjeh IJ, Cerhan JR, et al. Does antioxidant supplementation reduce primary cancer incidence and mortality? Systematic review and meta analysis. Abstract A159. American Association for Cancer Research, Frontiers in Cancer Prevention Research Meeting. Boston, Nov 13, 2006.
- Bartali B, Semba RD, Frongillo EA, et al. Low micronutrient levels as a predictor of incident disability in older women. *Arch Intern Med* 2006;166:2335-2340.
- Bates CJ, Thane CW, Prentice A, et al. Selenium status and its correlates in a British national diet and nutrition survey: people aged 65 years and over. *J Trace Elem Med Biol* 2002;16(1):1-8.
- Beazley WD, Gaze D, Panske A, et al. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. *Br J Dermatol* 1999;141(2):301-303.
- Beyrouty P, Chan HM. Co-consumption of selenium and vitamin E altered the reproductive and developmental toxicity of methylmercury in rats. *Neurotoxicol Teratol* 2006;28(1):49-58.
- Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. *Cancer Treat Rev* 2007;33(5):407-418. Epub 2007 March 23.
- Boik J. Natural compounds in cancer therapy. Princeton, MN: Oregon Medical Press, LLC; 2001.
- Bratter P, Negretti dB V. Influence of high dietary selenium intake on the thyroid hormone level in human serum. *J Trace Elem Med Biol* 1996;10(3):163-166.
- Brouwer CA, Gietema JA, van den Berg MP, et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006;17(10):1586-1591.
- Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. *Cancer Chemother Pharmacol* 2000;46(1):74-78.
- Caffrey PB, Zhu M, Frenkel GD. Prevention of the development of melphalan resistance in vitro by selenite. *Biol Trace Elem Res* 1998;65(3):187-195.
- Chen J, Berry MJ. Selenium and selenoproteins in the brain and brain diseases. *J Neurochem* 2003;86(1):1-12.
- Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in U.S. counties. *Arch Environ Health* 1991;46(1):37-42.
- Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial: Nutritional Prevention of Cancer Study Group. *JAMA* 1996;276(24):1957-1963.
- Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol* 1998;81(5):730-734.

Citations and Reference Literature: Selenium

- Clark RF, Strukle E, Williams SR, et al. Selenium poisoning from a nutritional supplement. *JAMA* 1996;275(14):1087-1088.
- Cohen HJ, Chovanec ME, Mistretta D, et al. Selenium repletion and glutathione peroxidase: differential effects on plasma and red blood cell enzyme activity. *Am J Clin Nutr* 1985;41(4):735-747.
- Combs GF Jr. Impact of selenium and cancer-prevention findings on the nutrition-health paradigm. *Nutr Cancer* 2001;40(1):6-11.
- Dong Y, Zhang H, Hawthorn L, et al. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. *Cancer Res* 2003;63(1):52-59.
- Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU Int* 2003;91(7):608-612.
- Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the nutritional prevention of cancer trial. *Cancer Epidemiol Biomarkers Prev* 2002;11(7):630-639.
- Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2003;95:1477-1481.
- El Bayoumy K. The protective role of selenium on genetic damage and on cancer. *Mutat Res* 2001;475(1-2):123-139.
- El-Bayoumy K, Richie JP Jr, Boyiri T, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. *Cancer Epidemiol Biomarkers Prev* 2002;11(11):1459-1465.
- Finley JW. Reduction of cancer risk by consumption of selenium-enriched plants: enrichment of broccoli with selenium increases the anticarcinogenic properties of broccoli. *J Med Food* 2003;6(1):19-26.
- Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, et al. Selenium and coronary heart disease: a meta-analysis. *Am J Clin Nutr* 2006;84:762-773. (Meta-analysis)
- Gartner R, Albrich W, Angstwurm MW. The effect of a selenium supplementation on the outcome of patients with severe systemic inflammation, burn and trauma. *Biofactors* 2001;14(1-4):199-204.
- Gasmi A, Garnier R, Galliot-Guilley M, et al. Acute selenium poisoning. *Vet Hum Toxicol* 1997;39(5):304-308.
- Greenwald P, Milner JA, Anderson DE, et al. Micronutrients in cancer chemoprevention. *Cancer Metastasis Rev* 2002;21(3-4):217-230.
- Griffiths JC, Matulka RA, Power R. Genotoxicity studies on sel-plex(r), a standardized, registered high-selenium yeast. *Int J Toxicol* 2006;25(6):477-485.
- Halliwell B, Gutteridge JMC. In: *Free radicals in biology and medicine*. 3rd ed. New York: Oxford University Press; 1999:1-936.
- Hamilton KK. Antioxidant supplements during cancer treatments: where do we stand? *Clin J Oncol Nurs* 2001;5(4):181-182. (Review)
- Hatanaka N, Nakaden H, Yamamoto Y, et al. Selenium kinetics and changes in glutathione peroxidase activities in patients receiving long-term parenteral nutrition and effects of supplementation with selenite. *Nutrition* 2000;16(1):22-26.
- Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst* 2000;92(24):2018-2023.
- Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. *Arch Intern Med* 2004;164:2335-2342.
- Holben DH, Smith AM. The diverse role of selenium within selenoproteins: a review. *J Am Diet Assoc* 1999;99(7):836-843.
- Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. *Cancer Res* 2003;63(12):3347-3351.
- Hunter DJ, Morris JS, Stampfer MJ, et al. A prospective study of selenium status and breast cancer risk. *JAMA* 1990;264(9):1128-1131.
- Ip C. Interaction of vitamin C and selenium supplementation in the modification of mammary carcinogenesis in rats. *J Natl Cancer Inst* 1986;77(1):299-303.
- Karunasinghe N, Ferguson LR, Tuckey J, et al. Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. *J Nutr* 2006;136(8):2232-2235.
- King WW, Michel L, Wood WC, et al. Reversal of selenium deficiency with oral selenium. *N Engl J Med* 1981;304(21):1305.
- Klein EA, Lippman SM, Thompson IM, et al. The selenium and vitamin E cancer prevention trial. *World J Urol* 2003;21(1):21-27.
- Kubena KS, McMurray DN. Nutrition and the immune system: a review of nutrient-nutrient interactions. *J Am Diet Assoc* 1996;96(11):1156-1164.
- Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. *Altern Med Rev* 1999;4(5):304-329.
- Lane HW, Lotspeich CA, Moore CE, et al. The effect of selenium supplementation on selenium status of patients receiving chronic total parenteral nutrition. *JPEN J Parenter Enteral Nutr* 1987;11(2):177-182.
- Lehmann C, Weber M, Krausch D, et al. Parenteral selenium supplementation in critically ill patients: effects on antioxidant metabolism. *Z Ernahrungswiss* 1998;37(Suppl 1):106-109.

Citations and Reference Literature: Selenium

- Levander OA, Whanger PD. Deliberations and evaluations of the approaches, endpoints and paradigms for selenium and iodine dietary recommendations. *J Nutr* 1996;126(9 Suppl):2427S-2434S.
- Last KW, Cornelius V, Delves T, et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2003;21(12):2335-2341.
- Liu D, Liu S, Huang Y, et al. Effect of selenium on human myocardial glutathione peroxidase gene expression. *Chin Med J (Engl)* 2000;113(9):771-775.
- Lloyd B, Robson E, Smith I, et al. Blood selenium concentrations and glutathione peroxidase activity. *Arch Dis Child* 1989;64(3):352-356.
- Mahabir S, Spitz MR, Barrera SL, et al. Dietary zinc, copper and selenium, and risk of lung cancer. *Int J Cancer* 2006.Epub ahead of print.
- Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. *J Natl Cancer Inst* 2000;92(21):1753-1763.
- McGuire MK, Burgert SL, Milner JA, et al. Selenium status of infants is influenced by supplementation of formula or maternal diets. *Am J Clin Nutr* 1993;58(5):643-648.
- Neve J. Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. *J Trace Elem Med Biol* 1995;9(2):65-73.
- Olivieri O, Girelli D, Stanzial AM, et al. Selenium, zinc, and thyroid hormones in healthy subjects: low T3/T4 ratio in the elderly is related to impaired selenium status. *Biol Trace Elem Res* 1996;51(1):31-41.
- Rebsch CM, Penna FJ III, Copeland PR. Selenoprotein expression is regulated at multiple levels in prostate cells. *Cell Res* 2006;16(12):940-948.
- Rotruck JT, Pope AL, Ganther HE, et al. Selenium: biochemical role as a component of glutathione peroxidase. *Science* 1973;179(73):588-590.
- Schwedhelm E, Maas R, Troost R, et al. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. *Clin Pharmacokinet* 2003;42(5):437-459.
- Seppanen K, Kantola M, Laatikainen R, et al. Effect of supplementation with organic selenium on mercury status as measured by mercury in pubic hair. *J Trace Elem Med Biol* 2000;14(2):84-87.
- Steinbrenner H, Bilgic E, Alili L, et al. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. *Free Radic Res* 2006;40(9):936-943.
- Stewart MS, Spallholz JE, Neldner KH, et al. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. *Free Radic Biol Med* 1999;26(1-2):42-48.
- Stranges S, Marshall JR, Trevisan M, et al. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. *Am J Epidemiol* 2006;163(8):694-699.
- Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. *Int J Cancer* 2003;103(5):664-670.
- Wei WQ, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. *Am J Clin Nutr* 2004;79(1):80-85.
- Whanger PD, Beilstein MA, Thomson CD, et al. Blood selenium and glutathione peroxidase activity of populations in New Zealand, Oregon, and South Dakota. *FASEB J* 1988;2(14):2996-3002.
- Wilber CG. Toxicology of selenium: a review. *Clin Toxicol* 1980;17(2):171-230.
- Yang GQ, Ge KY, Chen JS, et al. Selenium-related endemic diseases and the daily selenium requirement of humans. *World Rev Nutr Diet* 1988;55:98-152.
- Yang GQ, Xia YM. Studies on human dietary requirements and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. *Biomed Environ Sci* 1995;8:187-201.
- Zachara BA, Gromadzinska J, Wasowicz W, et al. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. *Acta Biochim Pol* 2006.Epub ahead of print.